2. Academic Validation
  3. Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors

Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors

  • J Med Chem. 2012 Nov 26;55(22):10229-40. doi: 10.1021/jm3012933.
Michael Lainchbury 1,  Thomas P Matthews,  Tatiana McHardy,  Kathy J Boxall,  Michael I Walton,  Paul D Eve,  Angela Hayes,  Melanie R Valenti,  Alexis K de Haven Brandon,  Gary Box,  G Wynne Aherne,  John C Reader,  Florence I Raynaud,  Suzanne A Eccles,  Michelle D Garrett,  Ian Collins
Affiliations

Affiliation

  • 1 Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG U. K.
PMID: 23082860 DOI: 10.1021/jm3012933
Abstract

Inhibitors of checkpoint kinase 1 (Chk1) are of current interest as potential antitumor agents, but the most advanced inhibitor series reported to date are not orally bioavailable. A novel series of potent and orally bioavailable 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitrile Chk1 inhibitors was generated by hybridization of two lead scaffolds derived from fragment-based drug design and optimized for Chk1 potency and high selectivity using a cell-based assay cascade. Efficient in vivo pharmacokinetic assessment was used to identify compounds with prolonged exposure following oral dosing. The optimized compound (CCT244747) was a potent and highly selective Chk1 Inhibitor, which modulated the DNA damage response pathway in human tumor xenografts and showed antitumor activity in combination with genotoxic chemotherapies and as a single agent.

Figures
Products